• Dr. Werner Braun Chairman of the board and Board member since 2016

    Dr. Werner Braun has international experience from leading positions in companies from Germany, Austria and Schwitzerland. Dr. Werner Braun is a doctor in physics from the Technical University of Munich, Germany.

    Acarix shareholdings:
    None

  • Claus Andersson, MSc, PhD Board member since 2010

    Dr. Claus Andersson is a partner in the venture capital Sunstone Capital. Dr. Claus Andersson has been member of the board in 17 companies, in six of these Chairman of the board. Present assignments include amongst others Cantargia AB and FBC Device ApS. Dr. Claus Andersson has 12 years of experience within venture capital, an industrial background within blood diagnostics founding four companies in Europe since year 2000, and kept a strong collaboration to University of Copenhagen, Denmark. Dr. Claus Andersson is educated as a civil engineer in chemistry and has a PhD in mathematical statistics from University of Copenhagen and Humbold University in Berlin.

    Acarix shareholdings:
    None

  • Denis Gestin Board member since 2016

    Denis Gestin has a degree in economy from EDC Paris Business School, France. Denis Gestin has been the President of International Division at St. Jude Medical Inc. since January 2008 and brings in-depth knowledge of cardiac device development and marketing.

    Acarix shareholdings:
    None

  • Hong Yun Fei Board member since 2016

    Hong Yun Fei holds a MSc degree in Pharmaceutical science. Hong Yun Fei is presently CSO in the Chinese listed company ZheJiangJingxin Pharmaceutical Co. LTD. and has 12 years of experience from the company from R&D, to strategy and investment. Hong Yun Fei has also been a director of 3 companies, also been the consultant of 2 Chinese venture capital. Hong Yun Fei has good relationship with Chinese Universities Fudan University and ZheJiang University.

    Acarix shareholdings:
    None

  • Oliver Johansen, M.Sc. (Industrial Eng.) Board member since 2015

    Oliver Johansen is Senior Vice President for research and development in Coloplast A/S and also member of the executive committee. Within Coloplast A/S Oliver Johansen is responsible for the process from initial innovation to concept development, product and process development, pilot production, global production and launch. Prior to joining Coloplast A/S Oliver Johansen hold positions within PriceWaterhouseCoopers, i2-Technologies A/S and Valcon A/S. Oliver Johansen has a masters degree in industrial engineering from The Technical University of Denmark.

    Acarix shareholdings:
    None

     

  • Ulf Rosén, Partner Board member since 2014

    Ulf Rosén is General Partner at the investment company SEED Capital responsible for investments in medical technology and Digital Health Solutions. He has since end of 1990-ties been Chairman of the board, member of the board and CEO in a number of Scandinavian companies within medical technology, pharma- and service sector. Ulf Roséns earlier assignments include, amongst other, CEO in NeoPharma AB (trade sale), CEO Attana AB (asset transfer), Chaiman of the board in Trial Form Support International (partial exit to PE), member of the board in Observe Medical AB (trade sale), General Manager in Fresenius-Kabi AB, vice-CEO in Global Nutrion Division in Fresenius-Kabi, CEO in Pharmacia & Upjohn AS and CEO in Globen Ögonklinik AB.

    Acarix shareholdings:
    None